Red Blood Cell Antigen Genotyping for Sickle Cell Disease, Thalassemia, and Other Transfusion Complications

Transfusion Medicine Reviews

Volumn 30, Issue 4, 2016, Pages 197-201

  Fasano, Ross M ^a   Chou, Stella T ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alloimmunization; Autoimmune hemolytic anemia; Red blood cell antigen genotyping; Rh; Sickle cell disease; Thalassemia

Indexed keywords

ALLOANTIBODY; AUTOANTIBODY; ERYTHROCYTE ANTIGEN; RHESUS ANTIGEN; BLOOD GROUP ANTIGEN;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD DONOR; BLOOD GROUP ABO SYSTEM; BLOOD GROUP RHESUS SYSTEM; BLOOD TRANSFUSION REACTION; CELL SELECTION; ERYTHROCYTE TRANSFUSION; FOOD AND DRUG ADMINISTRATION; GENE; GENETIC VARIABILITY; GENOTYPE; HEMAGGLUTINATION TEST; HUMAN; MOLECULAR GENETICS; PHENOTYPE; REVIEW; RH GENE; RHCE GENE; RHD GENE; SEROLOGY; SICKLE CELL ANEMIA; THALASSEMIA; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUP TYPING; BLOOD TRANSFUSION; CHEMISTRY; DNA SEQUENCE; ERYTHROCYTE; FEMALE; GENETIC VARIATION; GENETICS; HEMATOLOGY; HEMOGLOBINOPATHY; PREGNANCY; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANEMIA, SICKLE CELL; AUTOANTIBODIES; BLOOD GROUP ANTIGENS; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUPING AND CROSSMATCHING; BLOOD TRANSFUSION; ERYTHROCYTES; FEMALE; GENETIC VARIATION; GENOTYPE; HEMATOLOGY; HEMOGLOBINOPATHIES; HUMANS; ISOANTIBODIES; PHENOTYPE; PREGNANCY; RH-HR BLOOD-GROUP SYSTEM; SEQUENCE ANALYSIS, DNA; THALASSEMIA; TRANSFUSION REACTION; TREATMENT OUTCOME;

EID: 84994845466     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2016.05.011     Document Type: Review

References (37)

1. [1] Svensson, AM, Delaney, M, Considerations of red blood cell molecular testing in transfusion medicine. Expert Rev Mol Diagn 15 (2015), 1455–1464.
2. [2] Flegel, WA, Gottschall, JL, Denomme, GA, Integration of red cell genotyping into the blood supply chain: a population-based study. Lancet Haematol 2 (2015), e282–e288.
3. [3] Chou, ST, Liem, RI, Thompson, AA, Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol 159 (2012), 394–404.
4. [4] Yawn, BP, Buchanan, GR, Afenyi-Annan, AN, Ballas, SK, Hassell, KL, James, AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 312 (2014), 1033–1048.
5. [5] Fasano, RM, Meier, ER, Hulbert, ML, Cerebral vasculopathy in children with sickle cell anemia. Blood Cells Mol Dis 54 (2015), 17–25.
6. [6] Cazzola, M, Borgna-Pignatti, C, Locatelli, F, Ponchio, L, Beguin, Y, De Stefano, P, A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 37 (1997), 135–140.
7. [7] Matteocci, A, Pierelli, L, Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing. Vox Sang 106 (2014), 197–208.
8. [8] Chou, ST, Fasano, RM, Management of Patients with sickle cell disease using transfusion therapy: guidelines and complications. Hematol Oncol Clin North Am, 2016 [in press].
9. [9] Chou, ST, Jackson, T, Vege, S, Smith-Whitley, K, Friedman, DF, Westhoff, CM, High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 122 (2013), 1062–1071.
10. [10] Sippert, E, Fujita, CR, Machado, D, Guelsin, G, Gaspardi, AC, Pellegrino, J Jr., et al. Variant RH alleles and Rh immunisation in patients with sickle cell disease. Blood Transfus 13 (2015), 72–77.
11. [11] Thompson, AA, Cunningham, MJ, Singer, ST, Neufeld, EJ, Vichinsky, E, Yamashita, R, et al. Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Haematol 153 (2011), 121–128.
12. [12] Ahrens, N, Pruss, A, Kahne, A, Kiesewetter, H, Salama, A, Coexistence of autoantibodies and alloantibodies to red blood cells due to blood transfusion. Transfusion 47 (2007), 813–816.
13. [13] Hosseini-Maaf, B, Hellberg, A, Chester, MA, Olsson, ML, An extensive polymerase chain reaction-allele-specific polymorphism strategy for clinical ABO blood group genotyping that avoids potential errors caused by null, subgroup, and hybrid alleles. Transfusion 47 (2007), 2110–2125.
14. [14] Denomme, GA, Westhoff, CM, The Rh system. Fung, M.K., (eds.) Technical manual, 2014, AABB Press, Bethesda MD, 317–336.
15. [15] Liu, Z, Liu, M, Mercado, T, Illoh, O, Davey, R, Extended blood group molecular typing and next-generation sequencing. Transfus Med Rev 28 (2014), 177–186.
16. [16] Tilley, L, Grimsley, S, Is next generation sequencing the future of blood group testing?. Transfus Apher Sci 50 (2014), 183–188.
17. [17] Veldhuisen, B, van der Schoot, CE, de Haas, M, Blood group genotyping: from patient to high-throughput donor screening. Vox Sang 97 (2009), 198–206.
18. [18] Casas, J, Friedman, DF, Jackson, T, Vege, S, Westhoff, CM, Chou, ST, Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease. Transfusion 55 (2015), 1388–1393.
19. [19] B.P.A. Committee, Evaluation of the safety and effectiveness of the Immucor PreciseType™ HEA molecular BeadChip assay, manufactured by BioArray solutions limited [transcript from March 18–19, 2014]. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/ucm386681.htm, 2014 [Accessed: February 20 2016].
20. [20] Boccoz, SA, Blum, LJ, Marquette, CA, DNA biosensor/biochip for multiplex blood group genotyping. Methods 64 (2013), 241–249.
21. [21] Avent, ND, Large-scale blood group genotyping: clinical implications. Br J Haematol 144 (2009), 3–13.
22. [22] Meyer, S, Vollmert, C, Trost, N, Bronnimann, C, Gottschalk, J, Buser, A, et al. High-throughput Kell, Kidd, and Duffy matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry-based blood group genotyping of 4000 donors shows close to full concordance with serotyping and detects new alleles. Transfusion 54 (2014), 3198–3207.
23. [23] Lane, WJ, Westhoff, CM, Uy, JM, Aguad, M, Smeland-Wagman, R, Kaufman, RM, et al. Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing: proof of principle. Transfusion, 2015.
24. [24] Sapatnekar, S, Figueroa, PI, How do we use molecular red blood cell antigen typing to supplement pretransfusion testing?. Transfusion 54 (2014), 1452–1458.
25. [25] Buchanan, G, Yawn, B, Afenyi-Annan, A, Ballas, S, James, A, Jordan, L, et al. Evidence-based management of sickle cell disease: expert panel report, 2014. 2014, National Institutes of Health [Available at: http://www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/sickle-cell-disease-report.pdf].
26. [26] Rampersad, A, Hampton, K, Duncan, N, Roberson, C, Slayten, J, Davisson, S, et al. Noninvasive buccal swab antigen sample and molecular testing provides extended antigen typing for patients with hemoglobinopathies. J Pediatr 165 (2014), 1003–1007.
27. [27] Meny, GM, The Duffy blood group system: a review. Immunohematology 26 (2010), 51–56.
28. [28] Tournamille, C, Colin, Y, Cartron, JP, Le Van Kim, C, Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet 10 (1995), 224–228.
29. [29] Reid, ME, Lomas-Francis, C, Olsson, ML, The blood group antigen facts book. 3rd ed., 2012, Elsevier Academic Press.
30. [30] Tournamille, C, Meunier-Costes, N, Costes, B, Martret, J, Barrault, A, Gauthier, P, et al. Partial C antigen in sickle cell disease patients: clinical relevance and prevention of alloimmunization. Transfusion 50 (2010), 13–19.
31. [31] Lasalle-Williams, M, Nuss, R, Le, T, Cole, L, Hassell, K, Murphy, JR, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 51 (2011), 1732–1739.
32. [32] Tahhan, HR, Holbrook, CT, Braddy, LR, Brewer, LD, Christie, JD, Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion 34 (1994), 562–569.
33. [33] Wilkinson, K, Harris, S, Gaur, P, Haile, A, Armour, R, Teramura, G, et al. Molecular blood typing augments serologic testing and allows for enhanced matching of red blood cells for transfusion in patients with sickle cell disease. Transfusion 52 (2012), 381–388.
34. [34] Ribeiro, KR, Guarnieri, MH, da Costa, DC, Costa, FF, Pellegrino, J Jr., Castilho, L, DNA array analysis for red blood cell antigens facilitates the transfusion support with antigen-matched blood in patients with sickle cell disease. Vox Sang 97 (2009), 147–152.
35. [35] Shirey, RS, Boyd, JS, Parwani, AV, Tanz, WS, Ness, PM, King, KE, Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management. Transfusion 42 (2002), 1435–1441.
36. [36] Klapper, E, Zhang, Y, Figueroa, P, Ness, P, Stubbs, J, Abumuhor, I, et al. Toward extended phenotype matching: a new operational paradigm for the transfusion service. Transfusion 50 (2010), 536–546.
37. [37] Kappler-Gratias, S, Auxerre, C, Dubeaux, I, Beolet, M, Ripaux, M, Le Pennec, PY, et al. Systematic RH genotyping and variant identification in French donors of African origin. Blood Transfus 12:Suppl. 1 (2014), s264–s272.